Filing Flows › Integrated Biopharma (INBP) › Q3 FY26 › vs Q3 FY25
Integrated Biopharma (INBP) Q3 FY26 vs Q3 FY25 (year over year)
Integrated Biopharma's revenue fell $3.8M (-28%) from $13.9M in Q3 FY25 to $10.1M in Q3 FY26. The biggest changes: Contract Manufacturing −$3.6M (-27%); Other Nutraceutical Business −$204K (-42%).
Integrated Biopharma, Q3 FY26: revenue $10.1M (-28% year over year), operating margin -10.7%, net loss $837K, operating cash flow $517K. The chart draws each line against Q3 FY25, the increases inside each band.
Every line
| Line | Q3 FY26 | Q3 FY25 | Change | % |
|---|---|---|---|---|
| Contract Manufacturing | $9.8M | $13.5M | −$3.6M | -27% |
| Other Nutraceutical Business | $284K | $488K | −$204K | -42% |
| Revenue | $10.1M | $13.9M | −$3.8M | -28% |
| Other income, net | $50K | $39K | $11K | +28% |
| Income tax benefit | $198K | −$167K | $365K | — |
| Net loss | $837K | −$611K | $1.4M | — |
| Costs & expenses | $11.2M | $14.0M | −$2.8M | -20% |
| Operating costs | $11.2M | $13.2M | −$2.0M | -15% |
| Operating cash sources | $1.4M | $5K | $1.3M | 271× |
| Depreciation | $68K | $79K | −$11K | -14% |
| Share-based compensation | $50K | $45K | $5K | +11% |
| Working capital & other | $1.2M | −$119K | $1.4M | — |
| Net loss absorbed | $837K | −$611K | $1.4M | — |
| Operating cash flow | $517K | $616K | −$99K | -16% |
Questions
How much did Integrated Biopharma's revenue grow year over year in Q3 FY26?
Integrated Biopharma's revenue fell $3.8M (-28%) from $13.9M in Q3 FY25 to $10.1M in Q3 FY26.
What drove Integrated Biopharma's revenue change in Q3 FY26?
Contract Manufacturing −$3.6M (-27%); Other Nutraceutical Business −$204K (-42%).